

April 20, 2007


Center for Drug Evaluation and Research
Food and Drug Administration
5901 -B Ammendale Rd
Beltsville, MD 20705-1 266


Attn: Russell Katz, MD

**RE: IND 73,061: BG00012 (Dimethyl Fumarate): Multiple Sclerosis
Submission of Clinical Trial Protocols
Serial No.: 0017**

Dear Dr. Katz:

Reference is made to the End of Phase 2 meeting for Biogen Idec's product, BG00012 (dimethyl fumarate) held on August 30, 2006. At this meeting, the Agency requested that Biogen Idec submit the final study report for an ongoing 11-month chronic toxicology study in beagle dogs prior to the initiation of Phase 3 clinical trials.





Should you require any additional information, please contact Tammy Sarnelli, Associate Director, Regulatory Affairs at 617-679-3513. The contact for technical aspects for this submission is [REDACTED]

Sincerely yours

[REDACTED]
[REDACTED]
[REDACTED]